Xinyang Weikang

Shenzhen Xinyang Weikang Technology Co., Ltd. was established in 2015 and is located in the Returnees Innovation Park in Guangming District, Shenzhen. It is an innovative international pharmaceutical company built with an intelligent digital model by combining high-end crystal form formulation technology with quantum technology applications. The company has more than 1,000 square meters of international drug solid-state R&D laboratories, more than 1,500 square meters of specialized product development laboratories, and more than 3,000 square meters of GMP product production workshops under construction. The company has two core technologies: high-end drug crystal form formulation innovation and spectral intelligent identification technology, both of which are * new drug development technologies. Raman spectroscopy and intelligent data-assisted design simultaneously serve as cutting-edge new drug development technologies, filling a domestic gap and laying the foundation for personalized new drug development. Relying on its proprietary crystal engineering and special drug delivery system formulation technologies, the company takes "establishing an international pharmaceutical company with * advanced innovative drug delivery system products" as its core goal and develops cost-effective cutting-edge personalized drugs. At present, the product lines of its independently developed specialty new drugs are mainly divided into two major categories. The * category is the oral product line absorbed through gastrointestinal dissolution; the second major category is the transdermal product line that delivers drugs through the skin or mucosa. Xinyang's core technologies can break through barriers such as bioavailability, immediate delivery, time-sharing delivery, and local enhancement. The founding team, Dr. Tian Fang, Dr. Anne Zimmermann, and Dr. Cushla McGoverin, all come from Europe's first-class crystal form formulation R&D team and are among the earliest teams in the world to successfully apply Raman spectroscopy technology to crystal form research in liquid formulations. In addition to the founding team, the company currently has a group of senior full-time doctoral elites in the industry, who come from well-known universities at home and abroad such as the University of Oxford, Peking University, China Pharmaceutical University, Shenyang Pharmaceutical University, and the National University of Singapore. At the same time, Xinyang Weikang has also established an international scientific committee composed of five top global authoritative experts, including Prof. Stephen Bryn, Chairman of the Science Committee of the U.S. Food and Drug Administration (FDA), Prof. Thomas Rades, Chairman of the European Solid Drug Association, Prof. Keith Gordon, judge in the field of chemistry for the 2010 Nobel Prize, and Prof. Jukka Rantenen, Chairman of the Supervisory Committee of the European Federation for Pharmaceutical Sciences, among five professors. Our core values are "market-oriented, team-based, innovation as the soul, and talent as the core." We attract and gather a group of highly educated, high-quality, experienced, young, energetic, and creative talents. The company has no rigid and cumbersome rules and regulations or complicated interpersonal relationships, only an corporate culture and spirit that encourages technological innovation and entrepreneurial striving. The company is at the forefront of rapid development. If you want to prove yourself through your own efforts, if you want to fight side by side with world-class experts, if you want to create the future from a higher starting point, then come! Join us, together become a better us, and together become partners of the company!